Streptokinase, Recombinant

Recombinant Streptokinase is a non-glycosylated polypeptide chain containing 414 amino acids and having a molecular weight of 47kD.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity:\nStreptokinase is fully biologically active when compared to standard. One unit will liquify a standard clot of fibrinogen, plasminogen and thrombin at pH 7.5 at 37 degrees C in 10 min..\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of Streptokinase.\n\nReconstitution:\nReconstitute the lyophilized Streptokinase in sterile 18MHO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S7974-98G

Size

250KU

Form

Supplied as a lyophilized powder in HSA, sodium phosphate dibasic sodium phosphate monobasic buffer, sodium glutamate monohydrate.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Streptokinase and enoxaparin in the pre-hospital management of the ST-segment elevation acute myocardial infarction. Tatu-Chitoiu G, Oprisan M, Marinescu R, Rom J Intern Med 2002;40(1-4):11-25 2. Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction. Tatu-Chitoiu G, Teodorescu C, Capraru P, Bumbu A, Rom J Intern Med 2003;41(4):395-408 3. Intrapleural streptokinase in complicated parapneumonic effusions and empyema. Barthwal MS, Deoskar RB, Chatterjee RS, Indian J Chest Dis Allied Sci 2004 Oct-Dec;46(4):257-61 4. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. Kent DM, Vijan S, Griffith JL, J Clin Epidemiol 2004 Aug;57(8):843-52 5. Fibrinolytic treatment of complicated pediatric thoracic empyemas with intrapleural streptokinase. Ekingen G, Guvenc BH, Tuzlaci A, Eur J Cardiothorac Surg 2004 Sep;26(3):503-7 6. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin. Lopez M, Gonzalez LR, Sotolongo J, J Clin Pharm Ther 2004 Aug;29(4):367-73.